Publication

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity.

Journal Paper/Review - Sep 20, 2024

Units
PubMed
Doi
Contact

Citation
Lee S, Weiss T, Bühler M, Mena J, Lottenbach Z, Wegmann R, Sun M, Bihl M, Augustynek B, Baumann S, Goetze S, van Drogen A, Pedrioli P, Penton D, Festl Y, Buck A, Kirschenbaum D, Zeitlberger A, Neidert M, Vasella F, Rushing E, Wollscheid B, Hediger M, Weller M, Snijder B. High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nat Med 2024; 30:3196-3208.
Type
Journal Paper/Review (English)
Journal
Nat Med 2024; 30
Publication Date
Sep 20, 2024
Issn Electronic
1546-170X
Pages
3196-3208
Brief description/objective

Glioblastoma, the most aggressive primary brain cancer, has a dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we systematically screened repurposable neuroactive drugs in glioblastoma patient surgery material using a clinically concordant and single-cell resolved platform. Profiling more than 2,500 ex vivo drug responses across 27 patients and 132 drugs identified class-diverse neuroactive drugs with potent anti-glioblastoma efficacy that were validated across model systems. Interpretable molecular machine learning of drug-target networks revealed neuroactive convergence on AP-1/BTG-driven glioblastoma suppression, enabling expanded in silico screening of more than 1 million compounds with high patient validation accuracy. Deep multimodal profiling confirmed Ca-driven AP-1/BTG-pathway induction as a neuro-oncological glioblastoma vulnerability, epitomized by the anti-depressant vortioxetine synergizing with current standard-of-care chemotherapies in vivo. These findings establish an actionable framework for glioblastoma treatment rooted in its neural etiology.